Clinical Trials on Pedophilia in Poland

Total 128 results

Enzyre B.V.
Instytut Hematologii i Transfuzjologii, Warschau, Poland

Completed

Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem

Hemophilia A | Hemophilia A With Inhibitor

Poland
Grifols Biologicals, LLC

Completed

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Severe Hemophilia A

Poland
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years

Haemophilia B

Poland, Ukraine
Catalyst Biosciences

Completed

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Armenia, Georgia, South Africa, Poland, Russian Federation
Bio Products Laboratory

Completed

An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery

Haemophilia B

Poland, Romania, Russian Federation
Kathelijn Fischer
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Recruiting

Pharmacokinetic-guided Dosing of Emicizumab (DosEmi)

Adolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, Severe

Netherlands
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients

Haemophilia B

United Kingdom, Poland
Bayer

Completed

Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors (MATCHBOX)

Hemophilia A | Hemophilia B

South Africa, Poland, United Kingdom
Octapharma

Completed

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria, Poland, Hungary, Romania, Russian Federation
Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy...

Unknown

Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa (Thrombus)

Haemophilia

Poland
Baxalta now part of Shire

Completed

Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients

Hemophilia A

Czechia, Bulgaria, Hungary, Poland
Bio Products Laboratory

Terminated

Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A

Haemophilia A

Colombia, Germany, Poland
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.

Haemophilia A

Poland
Oregon Health and Science University

Completed

Comparison of Two Types of Ankle Braces in the Management of Ankle Pain in Hemophilia

Arthropathy Due to Bleeding From Hemophilia

United States
Pfizer

Completed

PF-06741086 Multiple Dose Study in Severe Hemophilia

Hemophilia A or B

United States, Chile, Croatia, Poland, South Africa, Switzerland
rEVO Biologics
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

United States, Bulgaria, Poland, Russian Federation, Belarus, Georgia, Israel, Romania, Ukraine, United Kingdom
Baxalta now part of Shire

Completed

BAX 326 Pediatric Study

Hemophilia B

Russian Federation, Ukraine, India, Poland, Romania, United Kingdom
Karolinska Institutet
National Institute of Mental Health, Czech Republic; Linköping University,... and other collaborators

Recruiting

Mi Bridge - Motivational Interviewing to Facilitate Help-seeking Among Minor Attracted Individuals (Mi Bridge)

Pedophilia | Child Sexual Abuse

Germany, Czechia, Finland, Slovakia, Spain, Sweden
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Haemophilia A

United Kingdom, Poland
Baxalta now part of Shire

Completed

BAX 326 Surgery Study in Hemophilia B Patients

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Czechia, Russian Federation, Ukraine, United Kingdom
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Pfizer

Completed

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Hemophilia A

United States, Argentina, Austria, Colombia, Croatia, Jordan, Mexico, New Zealand, Oman, Peru, Poland, Romania, Turkey
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
Octapharma

Completed

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Severe Hemophilia A

United States, France, Canada, United Kingdom, India, Georgia, Moldova, Republic of, Poland, Ukraine
Oregon Health and Science University
Baxter Healthcare Corporation

Completed

Prospective Biomarkers of Bone Metabolism in Hemophilia A

Hemophilia | Bone Disease

United States
Bloodworks
CSL Behring

Completed

Joint Health Study

Hemophilia B

United States
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Pfizer

Completed

Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B

Hemophilia B

Canada, Singapore, Turkey, Croatia, Korea, Republic of, Mexico, Poland, Bulgaria, Malaysia
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A

Spain, Canada, United States, New Zealand, Italy, Poland
Baxalta now part of Shire

Completed

IMMUNINE Pre-Treatment Study

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Brazil, Czechia, Russian Federation, Ukraine
St. Jude Children's Research Hospital
Children's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

Hemophilia B

United States, United Kingdom
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

United States, United Kingdom, Taiwan, Italy, Spain, India, Turkey, Malaysia, Russian Federation, Armenia, Georgia, Hungary, Mexico, Poland, South Africa, Ukraine
Oregon Health and Science University

Completed

Motor Proficiency of People With Bleeding Disorders Using the BOT-2 (TM)

Hemophilia

United States
Baxalta now part of Shire

Completed

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States, Poland, Slovenia, Greece, Russian Federation, Hungary, Italy, United Kingdom, Czechia, Austria
Bayer

Completed

Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Hemophilia A

Bulgaria, Spain, Italy, Poland, Greece, Norway, Denmark
CSL Behring
Parexel

Completed

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

Hemophilia A

Bulgaria, Poland, Russian Federation, Macedonia, The Former Yugoslav Republic of
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
Oregon Health and Science University

Completed

Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia

Hemophilia | Elbow Joint Contracture

United States
Bloodworks
Oregon Health and Science University; Seattle Children's Hospital; Providence...

Unknown

Comparison of Ideal vs. Actual Weight Base Factor Dosing

Hemophilia A

United States
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
Bayer

Completed

Colorado Adult Joint Assessment Scale (CAJAS) Validation (CAJAS)

Hemophilia A

United States
Oregon Health and Science University
American Thrombosis and Hemostasis Network

Completed

Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders

Hemophilia A | Bleeding Disorder

United States
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.

Haemophilia A

Poland, United Kingdom
Medexus Pharma, Inc.

Completed

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Hemophilia B

United States, France, United Kingdom, India, Israel, Italy, Poland
Baxalta now part of Shire

Completed

GAS-Hem Feasibility Study

Hemophilia A

Canada, United States
American Thrombosis and Hemostasis Network
Takeda; CSL Behring; Octapharma

Completed

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

Hemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without Inhibitor

United States
Bayer

Completed

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Hemophilia A, Hemophilia B

Italy, China, New Zealand, Russian Federation, Taiwan, Singapore, Bulgaria, United States, Denmark, Germany, Hungary, South Africa, United Kingdom, Romania, Colombia, Mexico, Turkey, France, India, Japan, Australia, Netherlands, Poland and more
Novo Nordisk A/S

Completed

High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United Kingdom, Spain, Israel, Poland, Turkey, Hungary
Baxalta now part of Shire

Active, not recruiting

Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

Hemophilia B

United States

Clinical Trials on Pedophilia in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations